@article{Beletsi2018-jr,
title = {Comparing Use of Health Technology Assessment in Pharmaceutical
Policy among Earlier and More Recent Adopters in the European
Union},
author = {Alexandra Beletsi and Vassiliki Koutrafouri and Eleftheria Karampli and Elpida Pavi},
year = {2018},
date = {2018-10-01},
journal = {Value Health Reg Issues},
volume = {16},
pages = {81--91},
address = {United States},
abstract = {OBJECTIVES: To examine and compare the use of health technology
assessment (HTA) for the reimbursement of new medicines in
selected European Union member states with decades of experience
in the use of HTA and in countries that have used it regularly
since 2000. METHODS: The selected countries were categorized into
``earlier'' adopters (group A: England, Germany, France, and
Sweden) and more ``recent'' adopters (group B: Poland, Bulgaria,
Hungary, and Romania). A systematic review of published
literature was performed. The analysis and comparison of HTA
procedures were done by using an analytical framework. RESULTS:
In all countries, the assessment criteria used include
effectiveness, safety, relative effectiveness, and economic data.
In group A countries, the main objectives are improving quality
of care, ensuring equal access, and efficient use of resources.
Group B countries have established HTA organizations with
official guidelines but often seek the decisions of other
developed countries. They place considerable emphasis on the
budget impact of new therapies, and HTA is also used as a cost
estimation tool for state budgets. CONCLUSIONS: HTA organizations
have been developed dynamically not only in high-income countries
but also in countries with limited resources. The experience and
evolution of both can be used by countries that are in the dawn
of creating an HTA organization.},
keywords = {health policies; health technology assessment; pharmacoeconomics; reimbursement},
pubstate = {published},
tppubtype = {article}
}
OBJECTIVES: To examine and compare the use of health technology
assessment (HTA) for the reimbursement of new medicines in
selected European Union member states with decades of experience
in the use of HTA and in countries that have used it regularly
since 2000. METHODS: The selected countries were categorized into
``earlier'' adopters (group A: England, Germany, France, and
Sweden) and more ``recent'' adopters (group B: Poland, Bulgaria,
Hungary, and Romania). A systematic review of published
literature was performed. The analysis and comparison of HTA
procedures were done by using an analytical framework. RESULTS:
In all countries, the assessment criteria used include
effectiveness, safety, relative effectiveness, and economic data.
In group A countries, the main objectives are improving quality
of care, ensuring equal access, and efficient use of resources.
Group B countries have established HTA organizations with
official guidelines but often seek the decisions of other
developed countries. They place considerable emphasis on the
budget impact of new therapies, and HTA is also used as a cost
estimation tool for state budgets. CONCLUSIONS: HTA organizations
have been developed dynamically not only in high-income countries
but also in countries with limited resources. The experience and
evolution of both can be used by countries that are in the dawn
of creating an HTA organization.